• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results

    2/23/21 4:10:00 PM ET
    $ACEV
    $AYTU
    $ASPL
    $PACE
    Semiconductors
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACEV alert in real time by email

    PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020.

    “Despite the unique challenges of 2020, Hercules was able to reach several new financial and operating milestones,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “Notably, we closed over $1.0 billion in new debt and equity commitments for the third consecutive year, delivered record total investment income and net investment income, each growing 7.2% and 9.7%, respectively, and maintained the strong credit quality of our debt investment portfolio. In addition, during Q4 our portfolio generated net investment income in excess of our base shareholder distribution and this allowed us to declare a $0.05 supplemental distribution to our shareholders.”

    Bluestein added, “Our Technology and Life Sciences segments continue to be well positioned throughout the COVID-19 pandemic. Access to liquidity for our portfolio companies continues to be strong as evidenced by record-breaking venture capital fundraising and investments in 2020.”

    Bluestein concluded, “As Hercules enters 2021, we do so from a position of strength with record liquidity, conservative leverage and strong originations momentum. We made significant investments throughout 2020 in our team, infrastructure and systems. We added talent to all levels of the organization and made a series of investments in our technology and systems that we believe will best position us for future growth.”

    Q4 2020 Review and Operating Results

    Debt Investment Portfolio

    Hercules delivered new debt and equity commitments totaling $150.8 million and gross fundings totaling $129.8 million.

    During the fourth quarter, Hercules realized early loan repayments of $282.3 million, which along with normal scheduled amortization of $18.3 million, resulted in total debt repayments of $300.5 million.

    The new debt investment origination and funding activities lead to a net debt investment portfolio decrease of ($184.2) million during the fourth quarter, on a cost basis.

    The Company’s total investment portfolio, (at cost and fair value) by category, quarter-over-quarter is highlighted below:

    Total Investment Portfolio: Q4 2020 to Q3 2020

    (in millions) Debt Equity & Inv.
    Funds
    Warrants Total Portfolio
    Balances at Cost at 9/30/20

    $

    2,283.7

     

     

    $

    193.3

     

     

    $

    28.8

     

     

    $

    2,505.8

     

    New fundings(a)

     

    122.2

     

     

     

    7.4

     

     

     

    0.2

     

     

     

    129.8

     

    Warrants not related to Q4 2020 fundings

     

    —

     

     

     

    —

     

     

     

    0.1

     

     

     

    0.1

     

    Early payoffs(b)

     

    (282.3

    )

     

     

    —

     

     

     

    —

     

     

     

    (282.3

    )

    Principal payments received on investments

     

    (18.3

    )

     

     

    —

     

     

     

    —

     

     

     

    (18.3

    )

    Net changes attributed to conversions, liquidations, and fees

     

    (5.8

    )

     

     

    (10.5

    )

     

     

    (3.4

    )

     

     

    (19.7

    )

    Net activity during Q4 2020

     

    (184.2

    )

     

     

    (3.1

    )

     

     

    (3.1

    )

     

     

    (190.4

    )

    Balances at Cost at 12/31/20

    $

    2,099.5

     

     

    $

    190.2

     

     

    $

    25.7

     

     

    $

    2,315.4

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Balances at Value at 9/30/20

    $

    2,264.5

     

     

    $

    133.8

     

     

    $

    22.5

     

     

    $

    2,420.8

     

    Net activity during Q4 2020

     

    (184.2

    )

     

     

    (3.1

    )

     

     

    (3.1

    )

     

     

    (190.4

    )

    Net change in unrealized appreciation (depreciation)

     

    14.2

     

     

     

    94.3

     

     

     

    15.2

     

     

     

    123.7

     

    Total net activity during Q4 2020

     

    (170.0

    )

     

     

    91.2

     

     

     

    12.1

     

     

     

    (66.7

    )

    Balances at Value at 12/31/20

    $

    2,094.5

     

     

    $

    225.0

     

     

    $

    34.6

     

     

    $

    2,354.1

     

     
    (a) New fundings amount includes $604K fundings associated with revolver loans during Q4 2020.
    (b) Early payoffs include $3.64 million of paydowns on revolvers during Q4 2020.

    Debt Investment Portfolio Balances by Quarter

    (in millions) Q4 2020 Q3 2020 Q2 2020 Q1 2020 Q4 2019
     
    Ending Balance at Cost

    $2,099.5

     

    $2,283.7

     

    $2,278.9

     

    $2,242.9

     

    $2,170.1

     

     

     

     

     

     

     

     

     

    Weighted Average Balance

    $2,246.0

     

    $2,217.0

     

    $2,248.0

     

    $2,178.0

     

    $2,164.0

     

    Debt Investment Portfolio Composition by Quarter

     
    (% of debt investment portfolio)

    Q4 2020

     

    Q3 2020

     

    Q2 2020

     

    Q1 2020

     

    Q4 2019

     

     

     

     

     

     

     

     

     

    First Lien Senior Secured

    84.2%

     

    85.5%

     

    83.5%

     

    83.0%

     

    84.0%

     

     

     

     

     

     

     

     

     

    Floating Rate w/Floors

    96.9%

     

    97.9%

     

    97.9%

     

    97.8%

     

    97.4%

     

    Effective Portfolio Yield and Core Portfolio Yield (“Core Yield”)

    The effective yield on Hercules’ debt investment portfolio was 13.3% during Q4 2020, as compared to 12.6% for Q3 2020. The Company realized $282.3 million of early loan repayments in Q4 2020 compared to $190.8 million in Q3 2020, or an increase of 48.0%. Effective yields generally include the effects of fees and income accelerations attributed to early loan repayments, and other one-time events. Effective yields are materially impacted by the elevated or reduced levels of early loan repayments and derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter, which excludes non-interest earning assets such as warrants and equity investments.

    Core yield, a non-GAAP measure, was 11.8% during Q4 2020, within the Company’s expected range of 11.0% to 12.0%, and increased compared to 11.3% in Q3 2020. Hercules defines core yield as yields that generally exclude any benefit from income related to early repayments attributed to the acceleration of unamortized income and prepayment fees and includes income from expired commitments.

    Income Statement

    Total investment income increased to $75.3 million for Q4 2020, compared to $70.6 million in Q4 2019, an increase of 6.7% year-over-year. The increase is primarily attributable to a higher weighted average debt investment balance and fee income from higher early loan repayments between periods.

    Non-interest and fee expenses were $16.0 million in Q4 2020 versus $14.5 million for Q4 2019. The increase was due to higher general and administrative expenses, tax expenses and higher employee compensation expenses.

    Interest expense and fees were $17.2 million in Q4 2020, compared to $16.0 million in Q4 2019. The increase was due to higher weighted-average borrowings between periods.

    The Company had a weighted average cost of borrowings comprised of interest and fees, of 5.2% in Q4 2020, as compared to 5.0% for Q4 2019.

    NII – Net Investment Income

    NII for Q4 2020 was $42.2 million, or $0.37 per share, based on 113.9 million basic weighted average shares outstanding, compared to $40.1 million, or $0.38 per share, based on 105.6 million basic weighted average shares outstanding in Q4 2019. The increase is attributable to a higher average debt investment balance and fee income from higher early loan repayments offset by an increase in total operating expenses and lower core yields between periods.

    Continued Credit Discipline and Strong Credit Performance

    Hercules’ net cumulative realized gain/(loss) position, since its first origination activities in October 2004 through December 31, 2020, (including net loan, warrant and equity activity) on investments, totaled ($79.7) million, on a GAAP basis, spanning over 16 years of investment activities.

    When compared to total new debt investment commitments during the same period of over $11.1 billion, the total realized gain/(loss) since inception of ($79.7) million represents approximately 72 basis points “bps,” or 0.72%, of cumulative debt commitments, or an effective annualized loss rate of 4.5 bps, or 0.04%.

    Realized Gains/(Losses)

    During Q4 2020, Hercules had net realized losses of ($14.7) million primarily from gross realized losses on the write-off or termination of equity, warrant and loan investments of ($22.4) million. These gross realized losses were offset by gross realized gains of $7.7 million due to the sale of the Company’s equity investments.

    Unrealized Appreciation/(Depreciation)

    During Q4 2020, Hercules recorded $123.7 million of net unrealized appreciation, all of which was net unrealized appreciation from our debt, equity and warrant investments.

    Portfolio Asset Quality

    As of December 31, 2020, the weighted average grade of the debt investment portfolio, at fair value, improved to 2.16, compared to 2.22 as of September 30, 2020, based on a scale of 1 to 5, with 1 being the highest quality. Hercules’ policy is to generally adjust the credit grading down on its portfolio companies as they approach their expected need for additional growth equity capital to fund their respective operations for the next 9-14 months. Various companies in the Company’s portfolio will require additional rounds of funding from time to time to maintain their operations.

    Additionally, Hercules may selectively downgrade portfolio companies, from time to time, if they are not meeting the Company’s financing criteria, or underperforming relative to their respective business plans.

    As of December 31, 2020, grading of the debt investment portfolio at fair value, excluding warrants and equity investments, was as follows:

    Credit Grading at Fair Value, Q4 2020 - Q4 2019 ($ in millions)

    Q4 2020

    Q3 2020

    Q2 2020

    Q1 2020

    Q4 2019

    Grade 1 - High

    $

    411.0

     

    19.6

    %

     

    $

    406.5

     

    17.9

    %

     

    $

    443.6

     

    20.1

    %

     

    $

    390.4

     

    17.7

    %

     

    $

    387.3

     

    18.0

    %

    Grade 2

    $

    1,027.9

     

    49.1

    %

     

    $

    1,053.1

     

    46.5

    %

     

    $

    877.9

     

    39.6

    %

     

    $

    818.1

     

    37.3

    %

     

    $

    1,180.5

     

    55.0

    %

    Grade 3

    $

    621.3

     

    29.7

    %

     

    $

    772.3

     

    34.1

    %

     

    $

    849.7

     

    38.3

    %

     

    $

    917.2

     

    41.8

    %

     

    $

    509.9

     

    23.7

    %

    Grade 4

    $

    25.3

     

    1.2

    %

     

    $

    26.7

     

    1.2

    %

     

    $

    25.0

     

    1.1

    %

     

    $

    54.3

     

    2.5

    %

     

    $

    69.0

     

    3.2

    %

    Grade 5 - Low

    $

    8.9

     

    0.4

    %

     

    $

    5.9

     

    0.3

    %

     

    $

    20.1

     

    0.9

    %

     

    $

    15.5

     

    0.7

    %

     

    $

    1.8

     

    0.1

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted Avg.

     

    2.16

     

     

     

     

    2.22

     

     

     

     

    2.30

     

     

     

     

    2.34

     

     

     

     

    2.15

     

     

    Non-Accruals

    Non-accruals increased as a percentage of the overall investment portfolio in the fourth quarter of 2020. As of December 31, 2020, the Company had seven (7) debt investments on non-accrual with an investment cost and fair value of approximately $31.0 million and $11.9 million, respectively, or 1.3% and 0.5% as a percentage of the Company’s total investment portfolio at cost and value, respectively.

    Compared to September 30, 2020, the Company had five (5) debt investments on non-accrual with an investment cost and fair value of approximately $23.5 million and $6.2 million, respectively, or 0.9% and 0.3% as a percentage of the total investment portfolio at cost and value, respectively.

    Q4 2020

     

    Q3 2020

     

    Q2 2020

     

    Q1 2020

     

    Q4 2019

     

     

     

     

     

     

     

     

     

    Total Investments at Cost

    $2,315.4

     

    $2,505.8

     

    $2,501.4

     

    $2,466.3

     

    $2,402.0

     

     

     

     

     

     

     

     

     

    Loans on non-accrual as a % of Total Investments at Value

    0.5%

     

    0.3%

     

    0.5%

     

    0.0%

     

    0.0%

     

     

     

     

     

     

     

     

     

    Loans on non-accrual as a % of Total Investments at Cost

    1.3%

     

    0.9%

     

    2.4%

     

    0.8%

     

    0.4%

    Liquidity and Capital Resources

    In November 2020, the Company announced a private offering totaling $100.0 million in aggregate principal amount of $50.0 million 4.50% Notes due March 2026 (the “March 2026 A Notes”) and $50.0 million 4.55% Notes due March 2026 (the “March 2026 B Notes”). The issuance of $50.0 million of the March 2026 A Notes occurred on November 4, 2020 and the issuance of $50.0 million of the March 2026 B Notes is expected to occur in March 2021.

    The Company ended Q4 2020 with $673.3 million in available liquidity, including $198.3 million in unrestricted cash and cash equivalents, and $475.0 million in available credit facilities, subject to existing terms and advance rates and regulatory and covenant requirements.

    During the three months ending December 31, 2020, the Company sold 306,000 shares of common stock under the equity ATM program, for total accumulated net proceeds of approximately $3.6 million, including $190,000 of offering expenses. During the twelve months ending December 31, 2020, the Company sold approximately 6.3 million shares of common stock, which were issued under the equity ATM program, for total accumulated net proceeds of approximately $77.2 million, including $1.0 of offering expenses, all accretive to net asset value. As of February 22, 2021, approximately 16.2 million shares remain available for issuance and sale under the Equity Distribution Agreement.

    On October 27, 2020, HC IV was licensed to operate as a Small Business Investment Company (SBIC) under the SBA. This additional license has a 10-year term. The Company will gain access to $175 million of capital through the SBA debenture program, in addition to its regulatory capital contribution of $87.5 million to HC IV which will be used for investment purposes, subject to the issuance of a capital commitment by the SBA and customary procedures.

    Bank Facilities

    As of December 31, 2020, there were no outstanding borrowings under the Hercules’ $400.0 million committed credit facility with Union Bank as Agent and no outstanding borrowings under the Hercules’ $75.0 million committed credit facility with Wells Fargo Capital Finance.

    Leverage

    As of December 31, 2020, Hercules’ GAAP leverage ratio, including its Small Business Administration “SBA” debentures, was 100.6%. Hercules’ regulatory leverage, or debt-to-equity ratio, excluding its SBA debentures, was 93.0% and net regulatory leverage, a non-GAAP measure (excluding cash of approximately $198.3 million), was 77.6%. Hercules’ net leverage ratio, including its SBA debentures, was 85.3%.

    Available Unfunded Commitments – Representing 6.9% of Total Assets

    The Company’s unfunded commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to select portfolio companies. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones in order to gain access to additional funding. Furthermore, the Company’s credit agreements contain customary lending provisions that allow us relief from funding obligations for previously made commitments. In addition, since a portion of these commitments may also expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements.

    As of December 31, 2020, the Company had $179.8 million of available unfunded commitments at the request of the portfolio company and unencumbered by any milestones, including undrawn revolving facilities, representing 6.9% of Hercules’ total assets. This decreased from the previous quarter of $242.5 million of available unfunded commitments or 9.7% of Hercules’ total assets.

    Existing Pipeline and Signed Term Sheets

    After closing $150.8 million in new debt and equity commitments in Q4 2020, Hercules has pending commitments of $248.0 million in signed non-binding term sheets outstanding as of February 18, 2021. Since the close of Q4 2020 and as of February 18, 2021, Hercules has closed new debt and equity commitments of $294.4 million and funded $196.3 million.

    Signed non-binding term sheets are subject to satisfactory completion of Hercules’ due diligence and final investment committee approval process as well as negotiations of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing. It is important to note that not all signed non-binding term sheets are expected to close and do not necessarily represent future cash requirements or investments.

    Net Asset Value

    As of December 31, 2020, the Company’s net assets were $1.29 billion, compared to $1.17 billion at the end of Q3 2020. NAV per share increased 9.7% to $11.26 on 114.7 million outstanding shares of common stock as of December 31, 2020, compared to $10.26 on 114.3 million outstanding shares of common stock as of December 31, 2020. The increase in NAV per share was primarily attributed to the net change in unrealized appreciation and earnings exceeding the distribution paid in Q4 of $0.05 per share.

    Interest Rate Sensitivity

    Hercules has an asset sensitive debt investment portfolio with 96.9% of its debt investment portfolio being priced at floating interest rates as of December 31, 2020, with a Prime or LIBOR-based interest rate floor, combined with 100% of its outstanding debt borrowings bearing fixed interest rates, leading to higher net investment income sensitivity.

    Based on Hercules’ Consolidated Statement of Assets and Liabilities as of December 31, 2020, the following table shows the approximate annualized increase/(decrease) in components of net income resulting from operations of hypothetical base rate changes in interest rates, such as Prime Rate, assuming no changes in Hercules’ debt investments and borrowings. These estimates are subject to change due to the impact from active participation in the Company’s equity ATM program and any future equity offerings.

     
    (in thousands) Interest Interest Net EPS(2)
    Basis Point Change Income(1) Expense Income

    (75)

    $

    (9

    )

    $

    (83

    )

    $

    74

    $

    -

    (50)

    $

    (9

    )

    $

    (55

    )

    $

    46

    $

    -

    (25)

    $

    (9

    )

    $

    (28

    )

    $

    19

    $

    -

    25

    $

    2,259

     

    $

    28

     

    $

    2,231

    $

    0.02

    50

    $

    4,517

     

    $

    55

     

    $

    4,462

    $

    0.04

    75

    $

    6,589

     

    $

    83

     

    $

    6,506

    $

    0.06

    100

    $

    8,907

     

    $

    110

     

    $

    8,797

    $

    0.08

    200

    $

    20,110

     

    $

    221

     

    $

    19,889

    $

    0.17

     
    (1) Source: Hercules Capital Form 10-K for Q4 2020
    (2) EPS calculated on basic weighted shares outstanding of 113,898. Estimates are subject to change due to impact from active participation in the Company's equity ATM program and any future equity offerings.

    Existing Equity and Warrant Portfolio

    Equity Portfolio

    Hercules held equity positions in 59 portfolio companies with a fair value of $224.7 million and a cost basis of $189.9 million as of December 31, 2020. On a fair value basis, 61.6% or $138.3 million is related to existing public equity positions.

    Warrant Portfolio

    Hercules held warrant positions in 100 portfolio companies with a fair value of $34.6 million and a cost basis of $25.7 million as of December 31, 2020. On a fair value basis, 38.0% or $13.1 million is related to existing public warrant positions.

    Portfolio Company IPO and M&A Activity in Q4 2020 and YTD 2021

    IPO Activity

    As of February 18, 2021, Hercules held debt, warrant or equity positions in two (2) portfolio companies that had completed their IPOs and five (5) companies that have entered into definitive agreements to go public via a special purpose acquisition company “SPAC,” including:

    • In December 2020, Hercules portfolio company DoorDash, Inc. (NYSE: DASH), a technology company that connects customers with local and national businesses in more than 4,000 cities and all 50 states across the United States, Canada, and Australia, completed its initial public offering of 33.0 million shares of common stock at an initial public offering price of $102.00 per share on the New York Stock Exchange. Hercules currently holds 525,000 shares of common stock as of December 31, 2020.
    • In December 2020, Hercules portfolio company 908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spectrometer devices for chemical and biomolecular analysis, completed its initial public offering at an initial public offering price of $20.00 per share on the Nasdaq Global Market. Hercules initially committed $15.0 million in venture debt financing beginning in February 2017 and currently holds warrants for 49,078 shares of common stock as of December 31, 2020.
    • In January 2021, Hercules portfolio company Achronix Semiconductor Corp., a semiconductor developer of FPGA and eFPGA devices, announced it has entered into a definitive agreement for a reverse merger initial public offering with ACE Convergence Acquisition Corp. (NASDAQ: ACEV), a special purpose acquisition company. Upon completion of the merger, Achronix will be listed on the Nasdaq Global Market under the ticker symbol “ACHX.” Hercules initially committed $38.0 million in venture debt financing beginning in June 2011 and currently holds warrants for 360,000 shares of Preferred Series C stock and 750,000 shares of Preferred Series D-2 stock as of December 31, 2020.
    • In February 2021, Hercules portfolio company Wheels Up Partners LLC, a provider of subscription club memberships for private-jet flyers, announced it has entered into a definitive agreement for a reverse merger initial public offering with Aspirational Consumer Lifestyle Corp. (NYSE: ASPL), a special purpose acquisition company. Upon completion of the merger, the Wheels Up will be listed on the New York Stock Exchange under the ticker symbol “UP.” Hercules initially committed $23.0 million in venture debt financing beginning in December 2017.
    • In January 2021, Hercules portfolio company Proterra, a leading commercial electric vehicle technology and manufacturing company, announced it has entered into a definitive agreement for a reverse merger initial public offering with ArcLight Clean Transition Corp. (NASDAQ: ACTC), a special purpose acquisition company. Upon completion of the merger, the Proterra will be listed on the Nasdaq Global Market under the ticker symbol “PTRA.” Hercules initially committed $30.0 million in venture debt financing beginning in May 2015 and currently holds warrants for 36,360 shares of common stock, warrants for 477,517 shares of Preferred Series 4 stock and 99,280 shares of Preferred Series 5 stock as of December 31, 2020.
    • In February 2021, Nerdy, the parent company of Hercules portfolio company Varsity Tutors, a technology developer of an online tutoring platform, announced it has entered into a definitive agreement for a reverse merger initial public offering with TPG Pace Tech Opportunities (NYSE: PACE), a special purpose acquisition company. Upon completion of the merger, Nerdy will be listed on the New York Stock Exchange under the ticker symbol “NRDY.” Hercules initially committed $50.0 million in venture debt financing beginning in August 2019.
    • In February 2021, Hercules portfolio company 23andMe Inc., a provider of consumer DNA-testing products, announced it has entered into a definitive agreement for a reverse merger initial public offering with VG Acquisition Corp. (NYSE: VGAC.U), a special purpose acquisition company. Upon completion of the merger, 23andMe will be listed on the New York Stock Exchange under the ticker symbol “ME.” Hercules currently holds 360,000 shares of common stock as of December 31, 2020.

    There can be no assurances that companies that have yet to complete their IPOs will do so.

    M&A Activity

    • In September 2020, Hercules’ portfolio company Insurance Technologies, LLC, a provider of sales and regulatory automation solutions for the insurance and financial services industries, announced that they entered into a definitive agreement with Thomas H. Lee Partners, a premier private equity firm investing in growth companies, under which Thomas H. Lee will acquire a majority stake in Insurance Technologies. Hercules initially committed $17.5 million in venture debt financing in March 2018.
    • In November 2020, Hercules’ portfolio company Postmates Inc., a leader in on-demand food delivery, announced that it has reached a definitive agreement to be acquired by Uber Technologies, Inc. (NYSE: UBER), a ride-hailing company offering services that include peer-to-peer ridesharing, ride service hailing, and food delivery, for approximately $2.65 billion in an all-stock transaction. The acquisition was completed in December 2020. Hercules initially committed $20.0 million in venture debt financing in July 2018 and currently holds 32,991 shares of Uber common stock as of December 31, 2020.
    • In November 2020, Hercules’ portfolio company Urovant Sciences (NASDAQ: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, announced that they have entered into a definitive merger agreement with Sumitovant Biopharma, a global biopharmaceutical company developing investigational medicines across a range of disease areas targeting high unmet need, for Sumitovant to acquire the outstanding shares of Urovant common stock not already owned by Sumitovant. Hercules initially committed $45.0 million in venture debt financing in February 2019 and currently holds warrants for 99,777 shares of common stock, as of December 31, 2020.
    • In December 2020, Hercules’ portfolio company Actifio Inc., a data management company that helps companies with data continuity to be better prepared in the event of a security breach or other need for disaster recovery, announced it reached an agreement to be acquired by Google. Terms of the acquisition were not disclosed. Hercules initially committed $40.0 million in venture debt financing beginning in July 2015.
    • In December 2020, Hercules portfolio company Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial stage pharmaceutical company developing and manufacturing central nervous system-focused products, announced that they entered into a definitive merger agreement with Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction. Hercules initially committed $26.5 million in venture debt financing beginning in March 2014 and currently holds 125,000 shares of common stock, as of December 31, 2020.
    • In January 2021, Hercules portfolio company Wattpad, the developer of a global multi-platform entertainment company for original stories and leading social storytelling platform, announced its unanimous approval of a definitive agreement to be acquired by Naver, South Korea’s internet conglomerate and home of WEBTOON™, a leading global digital comics platform. Naver is expected to acquire Wattpad in a cash and stock transaction valued at more than an estimated USD $600.0 million, subject to customary adjustments and other terms. Hercules initially committed $10.0 million in venture debt financing beginning in February 2016.

    Subsequent Events

    1. As of February 18, 2021, Hercules has:
      1. Funded $196.3 million to new and existing commitments since the close of the fourth quarter 2020.
      2. Pending commitments (signed non-binding term sheets) of $248.0 million.

    The table below summarizes the Company’s year-to-date closed and pending commitments as follows:

    Closed Commitments and Pending Commitments (in millions)

    Q1 2021 Closed Commitments (as of February 18, 2021)(a)

    $294.4

    Q1 2021 Pending Commitments (as of February 18, 2021)(b)

    $248.0

    Year-to-Date 2021 Closed and Pending Commitments

    $542.4

    Notes:

    1. Closed Commitments may include renewals of existing credit facilities and equity commitments. Not all Closed Commitments result in future cash requirements. Commitments generally fund over the two succeeding quarters from close.
    2. Not all pending commitments (signed non-binding term sheets) are expected to close and do not necessarily represent any future cash requirements.

    Conference Call

    Hercules has scheduled its fourth quarter and full-year 2020 financial results conference call for February 23, 2021 at 2:00 p.m. PT (5:00 p.m. ET). To listen to the call, please dial (877) 304-8957 (or (408) 427-3709 internationally) and reference Conference ID: 1585214 if asked, approximately 10 minutes prior to the start of the call. A taped replay will be made available approximately three hours after the conclusion of the call and will remain available for seven days. To access the replay, please dial (855) 859-2056 or (404) 537-3406 and enter the passcode 1585214.

    About Hercules Capital, Inc.

    Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $11.1 billion to over 520 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call 650.289.3060.

    Hercules’ common stock trades on the New York Stock Exchange (NYSE) under ticker symbol HTGC. In addition, Hercules has two retail bond issuances of 5.25% Notes due 2025 (NYSE: HCXZ) and 6.25% Notes due 2033 (NYSE: HCXY).

    Category: Earnings

    Forward-Looking Statements

    This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports we file under the Exchange Act.

    The information disclosed in this press release is made as of the date hereof and reflects Hercules’ most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Hercules believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.

    HERCULES CAPITAL, INC.
    CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES
    (dollars in thousands, except per share data)
     
    December 31, 2020 December 31, 2019
    Assets
    Investments:
    Non-control/Non-affiliate investments (cost of $2,175,651 and $2,248,524, respectively)

    $

    2,288,338

     

    $

    2,232,972

     

    Control investments (cost of $65,257 and $65,333, respectively)

     

    57,400

     

     

    59,746

     

    Affiliate investments (cost of $74,450 and $88,175, respectively)

     

    8,340

     

     

    21,808

     

    Total investments in securities, at value (cost of $2,315,358 and $2,402,032, respectively)

     

    2,354,078

     

     

    2,314,526

     

    Cash and cash equivalents

     

    198,282

     

     

    64,393

     

    Restricted cash

     

    39,340

     

     

    50,603

     

    Interest receivable

     

    19,077

     

     

    20,207

     

    Right of use asset

     

    9,278

     

     

    11,659

     

    Other assets

     

    3,942

     

     

    580

     

    Total assets

    $

    2,623,997

     

    $

    2,461,968

     

     

     

     

    Liabilities

     

     

     

    Accounts payable and accrued liabilities

    $

    36,343

     

    $

    30,306

     

    Operating lease liability

     

    9,312

     

     

    11,538

     

    SBA Debentures, net (principal of $99,000 and $149,000, respectively)(1)

     

    98,716

     

     

    148,165

     

    2022 Notes, net (principal of $150,000 and $150,000, respectively)(1)

     

    149,039

     

     

    148,514

     

    July 2024 Notes, net (principal of $105,000 and $105,000, respectively)(1)

     

    103,942

     

     

    103,685

     

    February 2025 Notes, net (principal of $50,000 and $0, respectively)(1)

     

    49,522

     

     

    —

     

    April 2025 Notes, net (principal of $75,000 and $75,000, respectively)(1)

     

    73,351

     

     

    72,970

     

    June 2025 Notes, net (principal of $70,000 and $0, respectively)(1)

     

    69,272

     

     

    —

     

    March 2026 A Notes, net (principal of $50,000 and $0, respectively)(1)

     

    49,550

     

     

    —

     

    2033 Notes, net (principal of $40,000 and $40,000, respectively)(1)

     

    38,610

     

     

    38,501

     

    2027 Asset-Backed Notes, net (principal of $180,988 and $200,000 respectively)(1)

     

    178,812

     

     

    197,312

     

    2028 Asset-Backed Notes, net (principal of $250,000 and $250,000, respectively)(1)

     

    247,647

     

     

    247,395

     

    2022 Convertible Notes, net (principal of $230,000 and $230,000, respectively)(1)

     

    228,177

     

     

    226,614

     

    Credit Facilities

     

    —

     

     

    103,919

     

    Total liabilities

    $

    1,332,293

     

    $

    1,328,919

     

     

     

     

    Net assets consist of:

     

     

     

    Common stock, par value

     

    115

     

     

    108

     

    Capital in excess of par value

     

    1,158,198

     

     

    1,145,106

     

    Total distributable earnings (loss)

     

    133,391

     

     

    (12,165

    )

    Total net assets

    $

    1,291,704

     

    $

    1,133,049

     

    Total liabilities and net assets

    $

    2,623,997

     

    $

    2,461,968

     

     

     

     

    Shares of common stock outstanding ($0.001 par value, 200,000,000 authorized)

     

    114,726

     

     

    107,364

     

    Net asset value per share

    $

    11.26

     

    $

    10.55

     

     
    (1) The Company’s SBA Debentures, February 2025 Notes, June 2025 Notes, 2033 Notes, April 2025 Notes, 2022 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes, July 2024 Notes, and March 2026 A Notes, as each term is defined herein, are presented net of the associated debt issuance costs for each instrument.
    HERCULES CAPITAL, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS
    (in thousands, except per share data)
     
    Three Months Ended December 31, Twelve Months Ended December 31,

    2020

    2019

    2020

    2019

    Investment income:
    Interest and dividend income
    Non-control/Non-affiliate investments

    $

    67,581

     

     

    $

    64,925

     

     

    $

    259,989

     

     

    $

    241,491

     

    Control investments

     

    740

     

     

     

    894

     

     

     

    2,857

     

     

     

    4,014

     

    Affiliate investments

     

    (76

    )

     

     

    267

     

     

     

    533

     

     

     

    2,008

     

    Total interest income

     

    68,245

     

     

     

    66,086

     

     

     

    263,379

     

     

     

    247,513

     

    Fee income

     

     

     

     

     

     

     

    Non-control/Non-affiliate investments

     

    7,081

     

     

     

    4,486

     

     

     

    23,858

     

     

     

    20,157

     

    Control investments

     

    6

     

     

     

    5

     

     

     

    21

     

     

     

    18

     

    Affiliate investments

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    186

     

    Total fee income

     

    7,087

     

     

     

    4,491

     

     

     

    23,879

     

     

     

    20,361

     

    Total investment income

     

    75,332

     

     

     

    70,577

     

     

     

    287,258

     

     

     

    267,874

     

    Operating expenses:

     

     

     

     

     

     

     

    Interest

     

    15,190

     

     

     

    14,669

     

     

     

    59,605

     

     

     

    54,596

     

    Loan fees

     

    2,001

     

     

     

    1,285

     

     

     

    7,269

     

     

     

    7,078

     

    General and administrative

     

    4,725

     

     

     

    4,573

     

     

     

    18,910

     

     

     

    19,183

     

    Tax expenses

     

    1,257

     

     

     

    519

     

     

     

    4,285

     

     

     

    2,226

     

    Employee compensation

     

     

     

     

     

     

     

    Compensation and benefits

     

    6,421

     

     

     

    7,621

     

     

     

    28,996

     

     

     

    30,993

     

    Stock-based compensation

     

    3,576

     

     

     

    1,811

     

     

     

    11,053

     

     

     

    10,526

     

    Total employee compensation

     

    9,997

     

     

     

    9,432

     

     

     

    40,049

     

     

     

    41,519

     

    Total operating expenses

     

    33,170

     

     

     

    30,478

     

     

     

    130,118

     

     

     

    124,602

     

    Other income(loss)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Net investment income

     

    42,162

     

     

     

    40,099

     

     

     

    157,140

     

     

     

    143,272

     

    Net realized gain (loss) on investments

     

     

     

     

     

     

     

    Non-control/Non-affiliate investments

     

    (563

    )

     

     

    2,890

     

     

     

    (41,956

    )

     

     

    16,523

     

    Control investments

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Affiliate investments

     

    (14,149

    )

     

     

    —

     

     

     

    (14,149

    )

     

     

    —

     

    Total net realized gain (loss) on investments

     

    (14,712

    )

     

     

    2,890

     

     

     

    (56,105

    )

     

     

    16,523

     

    Net change in unrealized appreciation (depreciation) on investments

     

     

     

     

     

     

     

    Non-control/Non-affiliate investments

     

    108,756

     

     

     

    (458

    )

     

     

    128,238

     

     

     

    15,074

     

    Control investments

     

    2,292

     

     

     

    1,174

     

     

     

    (2,271

    )

     

     

    1,595

     

    Affiliate investments

     

    12,674

     

     

     

    906

     

     

     

    259

     

     

     

    (2,866

    )

    Total net unrealized appreciation (depreciation) on investments

     

    123,722

     

     

     

    1,622

     

     

     

    126,226

     

     

     

    13,803

     

    Total net realized and unrealized gain(loss)

     

    109,010

     

     

     

    4,512

     

     

     

    70,121

     

     

     

    30,326

     

    Net increase(decrease) in net assets resulting from operations

    $

    151,172

     

     

    $

    44,611

     

     

    $

    227,261

     

     

    $

    173,598

     

    Net investment income before investment gains and losses per common share:

     

     

     

     

     

     

     

    Basic

    $

    0.37

     

     

    $

    0.38

     

     

    $

    1.39

     

     

    $

    1.41

     

    Change in net assets resulting from operations per common share:

     

     

     

     

     

     

     

    Basic

    $

    1.32

     

     

    $

    0.42

     

     

    $

    2.02

     

     

    $

    1.71

     

    Diluted

    $

    1.31

     

     

    $

    0.42

     

     

    $

    2.01

     

     

    $

    1.71

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    113,898

     

     

     

    105,634

     

     

     

    111,985

     

     

     

    101,132

     

    Diluted

     

    114,263

     

     

     

    106,072

     

     

     

    112,267

     

     

     

    101,569

     

    Distributions paid per common share:

     

     

     

     

     

     

     

    Basic

    $

    0.34

     

     

    $

    0.35

     

     

    $

    1.38

     

     

    $

    1.33

     

     

    Get the next $ACEV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACEV
    $AYTU
    $ASPL
    $PACE

    CompanyDatePrice TargetRatingAnalyst
    908 Devices Inc.
    $MASS
    8/5/2025$12.00Market Perform → Outperform
    Leerink Partners
    DoorDash Inc.
    $DASH
    7/15/2025$250.00Hold → Buy
    Jefferies
    DoorDash Inc.
    $DASH
    7/15/2025$250.00Buy → Hold
    Jefferies
    DoorDash Inc.
    $DASH
    7/1/2025$225.00 → $265.00Buy
    BTIG Research
    Aytu BioPharma Inc.
    $AYTU
    7/1/2025$8.00Buy
    Lake Street
    Aytu BioPharma Inc.
    $AYTU
    6/30/2025$12.00Buy
    Ascendiant Capital Markets
    Uber Technologies Inc.
    $UBER
    6/27/2025$84.00Buy → Hold
    Canaccord Genuity
    DoorDash Inc.
    $DASH
    6/23/2025$260.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $ACEV
    $AYTU
    $ASPL
    $PACE
    SEC Filings

    View All

    SEC Form 13F-HR filed by Uber Technologies Inc.

    13F-HR - Uber Technologies, Inc (0001543151) (Filer)

    8/14/25 4:05:29 PM ET
    $UBER
    Real Estate

    SEC Form 144 filed by DoorDash Inc.

    144 - DoorDash, Inc. (0001792789) (Subject)

    8/11/25 4:22:51 PM ET
    $DASH
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by 908 Devices Inc.

    SCHEDULE 13G - 908 Devices Inc. (0001555279) (Subject)

    8/11/25 6:39:46 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    $ACEV
    $AYTU
    $ASPL
    $PACE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    908 Devices upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded 908 Devices from Market Perform to Outperform and set a new price target of $12.00

    8/5/25 1:46:38 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    DoorDash upgraded by Jefferies with a new price target

    Jefferies upgraded DoorDash from Hold to Buy and set a new price target of $250.00

    7/15/25 3:48:27 PM ET
    $DASH
    EDP Services
    Technology

    DoorDash downgraded by Jefferies with a new price target

    Jefferies downgraded DoorDash from Buy to Hold and set a new price target of $250.00

    7/15/25 8:36:16 AM ET
    $DASH
    EDP Services
    Technology

    $ACEV
    $AYTU
    $ASPL
    $PACE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Disbrow Jarrett bought $24,999 worth of shares (16,666 units at $1.50), increasing direct ownership by 130% to 29,462 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    6/10/25 3:06:06 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Disbrow Joshua R. bought $99,999 worth of shares (66,666 units at $1.50), increasing direct ownership by 77% to 153,257 units (SEC Form 4)

    4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

    6/10/25 3:04:30 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    6/5/25 6:38:34 PM ET
    $HTGC
    Investment Managers
    Finance

    $ACEV
    $AYTU
    $ASPL
    $PACE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Xu Tony gifted 80,000 shares, sold $69,408,326 worth of shares (291,403 units at $238.19), disposed of 227,547 shares and acquired 80,000 shares, decreasing direct ownership by 100% to 1,500 units (SEC Form 4)

    4 - DoorDash, Inc. (0001792789) (Issuer)

    8/22/25 4:15:37 PM ET
    $DASH
    EDP Services
    Technology

    CHIEF FINANCIAL OFFICER Inukonda Ravi sold $3,910,308 worth of shares (16,417 units at $238.19), decreasing direct ownership by 7% to 228,488 units (SEC Form 4)

    4 - DoorDash, Inc. (0001792789) (Issuer)

    8/22/25 4:15:24 PM ET
    $DASH
    EDP Services
    Technology

    GENERAL COUNSEL AND SECRETARY Sherringham Tia sold $2,244,190 worth of shares (9,422 units at $238.19), decreasing direct ownership by 7% to 120,092 units (SEC Form 4)

    4 - DoorDash, Inc. (0001792789) (Issuer)

    8/22/25 4:15:32 PM ET
    $DASH
    EDP Services
    Technology

    $ACEV
    $AYTU
    $ASPL
    $PACE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ("KBRA") has affirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the affirmation of the rating and stable outlook, as well as its underlying analysis. The affirmed BBB+ rating reflects the Company's diversified investment portfolio with a focus on senior secured first lien venture debt investments in the technology

    8/19/25 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    DoorDash and Ace Pickleball Club Announce Multi-Year Partnership to Bring On-Demand Convenience to Club Members Nationwide

    DoorDash integration makes it easier than ever for Ace Pickleball Club members to fuel up and play more. SAN FRANCISCO and ROSWELL, Ga., Aug. 14, 2025 /PRNewswire/ -- DoorDash and Ace Pickleball Club (APC), who specializes in developing indoor pickleball clubs and delivering exceptional member experiences, today announced a strategic multi-year partnership. As part of the agreement, DoorDash becomes the Official On-Demand Delivery & Pickup Platform of Ace Pickleball Club, delivering convenience directly to the courts. Through this partnership, DoorDash will offer exclusive ben

    8/14/25 9:05:00 AM ET
    $DASH
    EDP Services
    Technology

    McDonald's and DoorDash Expand Global Partnership with New Online Ordering Experience in U.S.

    The new, direct ordering channel from McDonalds.com, powered by DoorDash Online Ordering, offers customers even more options and convenience Ordering your McDonald's favorites directly to your door just got even easier. Today, McDonald's USA (NYSE:MCD) and DoorDash (NASDAQ:DASH) announced the launch of a new U.S. online ordering experience, allowing customers to order McDelivery via mobile web or desktop — no app downloads, logins, or accounts required. Orders are fulfilled by Dashers, offering a fast, reliable, and familiar delivery experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813041428/en/The new, direct ord

    8/13/25 9:01:00 AM ET
    $DASH
    $MCD
    EDP Services
    Technology
    Restaurants
    Consumer Discretionary

    $ACEV
    $AYTU
    $ASPL
    $PACE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

    Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-12) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 10/13/2023. Application Category: NDA, Application Number: 205489, Application Classification: Labeling

    10/16/23 4:40:20 AM ET
    $NEOS
    Major Pharmaceuticals
    Health Care

    FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

    Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-7) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 06/25/2021. Application Category: NDA, Application Number: 205489, Application Classification: Labeling

    6/28/21 5:08:40 AM ET
    $NEOS
    Major Pharmaceuticals
    Health Care

    FDA Approval for

    Submission status for UROVANT SCIENCES GMBH's drug (ORIG-1) with active ingredient has changed to 'Approval' on 12/23/2020. Application Category: NDA, Application Number: 213006, Application Classification: Type 1 - New Molecular Entity

    12/23/20 2:41:16 PM ET
    $UROV
    Major Pharmaceuticals
    Health Care

    $ACEV
    $AYTU
    $ASPL
    $PACE
    Leadership Updates

    Live Leadership Updates

    View All

    Serve Robotics and Little Caesars Launch Autonomous Robot Delivery Via Uber Eats

    SAN FRANCISCO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Serve Robotics Inc. (NASDAQ:SERV), a leading autonomous sidewalk delivery company, and Little Caesars, the nation's third-largest pizza chain, today announced a partnership to deliver the brand's iconic HOT-N-READY® pizza with Serve's autonomous delivery robots via Uber Eats (NYSE:UBER). Little Caesars customers in Serve's Los Angeles delivery area may now receive their orders via autonomous sidewalk robots. The partnership expands Serve's presence on Uber Eats—which already offers Serve's robotic deliveries in Los Angeles, Miami, Dallas and Atlanta—with additional U.S. cities coming soon. "Delivering for a beloved national chain like Litt

    8/5/25 4:15:00 PM ET
    $SERV
    $UBER
    Industrial Specialties
    Consumer Discretionary
    Real Estate

    Snappt Acquires Trigo to Enhance Applicant Trust Platform for Multifamily Housing, Secures $50M Growth Financing

    Strategic growth financing accelerates expansion through acquisition and supports product innovation Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifying rental payment history. Backed by a $50 million committed facility from Hercules Capital, Inc. (NYSE:HTGC), the acquisition expands Snappt's platform and strengthens its ability to help property managers make faster, more confident leasing decisions. Together, these milestones mark a major step toward building the industry's most complete and trusted solution embedded into the application and screening process. "This

    8/5/25 12:00:00 PM ET
    $HTGC
    Investment Managers
    Finance

    908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 15 years at the U.S. Department of Defense (DoD), Dr. Vann held several leadership positions overseeing nuclear, chemical, and biological defense programs. The company also announces that Jeff George, a veteran biopharma leader, has stepped down from its Board of Directors due to the company's strategic refocus on public health, safety and defense tech. These changes are effective immediately. Previously, Dr. Vann was Performing the Duties of the Assistant Secretary of Defense for Nuclear, Ch

    8/4/25 7:00:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    $ACEV
    $AYTU
    $ASPL
    $PACE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

    SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

    11/14/24 5:11:18 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

    SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

    11/14/24 4:25:10 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

    SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

    11/13/24 5:36:50 PM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACEV
    $AYTU
    $ASPL
    $PACE
    Financials

    Live finance-specific insights

    View All

    Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

    CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE:HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion;An exc

    8/8/25 7:45:00 AM ET
    $HRTX
    $HTGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Uber Announces Results for Second Quarter 2025

    Trips and Gross Bookings grew 18% year-over-year Income from operations of $1.5 billion; Adjusted EBITDA of $2.1 billion, up 35% year-over-year Operating cash flow of $2.6 billion and Free cash flow of $2.5 billion(1) New $20 billion share repurchase authorization Uber Technologies, Inc. (NYSE:UBER) today announced financial results for the quarter ended June 30, 2025. "Our platform strategy is working, with record audience, frequency, and profitability across Mobility and Delivery," said Dara Khosrowshahi, CEO. "But we're still only beginning to unlock the platform's full potential, now with 20 autonomous partners around the world." "Today's announcement of a new $20 billion share re

    8/6/25 6:55:00 AM ET
    $UBER
    Real Estate

    908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook

    Revenue from continuing operations grew 14% compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended June 30, 2025. "We executed with urgency and discipline in the second quarter, driving strong top-line growth while advancing key structural initiatives to strengthen our financial profile," said Kevin J. Knopp, CEO and Co-founder. "We delivered record XplorIR placements, successfully launched VipIR, and made meaningful progress on our path to profitability. These achievements reinforce our c

    8/5/25 7:00:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials